Match!
Tannishtha Reya
University of California, San Diego
HaematopoiesisWnt signaling pathwayImmunologyStem cellBiology
91Publications
32H-index
18.6kCitations
What is this?
Publications 83
Newest
#1Jeevisha BajajH-Index: 7
#2Michael HamiltonH-Index: 1
Last. David Rizzeri (Durham University)
view all 18 authors...
Aggressive myeloid leukemias such as blast crisis chronic myeloid leukemia and acute myeloid leukemia remain highly lethal. Here we report a genome-wide in vivo CRISPR screen to identify new dependencies in this disease. Among these, RNA-binding proteins (RBPs) in general, and the double-stranded RBP Staufen2 (Stau2) in particular, emerged as critical regulators of myeloid leukemia. In a newly developed knockout mouse, loss of Stau2 led to a profound decrease in leukemia growth and improved surv...
Source
#1Geoff Wahl (Salk Institute for Biological Studies)H-Index: 2
#2Zhibo Ma (Salk Institute for Biological Studies)H-Index: 1
Last. R Heinz (HCI: Huntsman Cancer Institute)
view all 25 authors...
Parallels among embryonic development, stem cells, and cancer have long been recognized. We identified, isolated, and characterized stem cells that first become committed to a mammary fate during embryogenesis; we refer to these cells as fetal mammary stem cells (fMaSCs). Lineage tracing, in vitro sphere formation, and in vivo transplantation studies by our group and many others all confirm that cells in the embryo are the bipotent progenitors of the mammary gland. There is debate, however, on w...
Source
While standard therapies can lead to an initial remission of aggressive cancers, they are often only a transient solution. The resistance and relapse that follows is driven by tumor heterogeneity and therapy-resistant populations that can reinitiate growth and promote disease progression. There is thus a significant need to understand the cell types and signaling pathways that not only contribute to cancer initiation, but also those that confer resistance and drive recurrence. Here, we discuss w...
Source
#1Lesley Paige Ferguson (UCSD: University of California, San Diego)
#2Jovylyn Gatchalian (Salk Institute for Biological Studies)H-Index: 2
Last. Tannishtha Reya (UCSD: University of California, San Diego)H-Index: 32
view all 12 authors...
Pancreatic adenocarcinoma (PDAC) is a devastating disease characterized by high rates of metastasis and poor therapeutic response. It is currently the 4th leading cause of cancer-related deaths in developed countries, and despite efforts to improve therapy, the five-year survival rate remains at 9%. Therefore, it is critical to identify new programs that drive pancreatic cancer progression and therapeutic resistance. To define new cancer dependencies, work in the Reya lab has focused on characte...
Source
#1Tannishtha Reya (UCSD: University of California, San Diego)H-Index: 32
Source
#1David PropperH-Index: 23
#2Haiyong HanH-Index: 33
Last. Gerard I. EvanH-Index: 74
view all 19 authors...
Source
#1Nikki K. Lytle (UCSD: University of California, San Diego)H-Index: 9
#2L. Paige Ferguson (UCSD: University of California, San Diego)H-Index: 1
Last. Tannishtha ReyaH-Index: 32
view all 33 authors...
Summary Drug resistance and relapse remain key challenges in pancreatic cancer. Here, we have used RNA sequencing (RNA-seq), chromatin immunoprecipitation (ChIP)-seq, and genome-wide CRISPR analysis to map the molecular dependencies of pancreatic cancer stem cells, highly therapy-resistant cells that preferentially drive tumorigenesis and progression. This integrated genomic approach revealed an unexpected utilization of immuno-regulatory signals by pancreatic cancer epithelial cells. In particu...
7 CitationsSource
#1Yu Shi (Salk Institute for Biological Studies)H-Index: 7
#2Weina Gao (SU: Southern University and A&M College)H-Index: 2
Last. Tony Hunter (Salk Institute for Biological Studies)H-Index: 155
view all 38 authors...
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis largely owing to inefficient diagnosis and tenacious drug resistance. Activation of pancreatic stellate cells (PSCs) and consequent development of dense stroma are prominent features accounting for this aggressive biology1,2. The reciprocal interplay between PSCs and pancreatic cancer cells (PCCs) not only enhances tumour progression and metastasis but also sustains their own activation, facilitating a vicious cycle to exacerbate tum...
11 CitationsSource
#1Kyle Spinler (UCSD: University of California, San Diego)
#2Tannishtha Reya (UCSD: University of California, San Diego)H-Index: 32
Last. Jeffrey D. Esko (UCSD: University of California, San Diego)H-Index: 77
view all 14 authors...
Source
#1Jeevisha Bajaj (UCSD: University of California, San Diego)H-Index: 7
#2James P. Scott-Browne (La Jolla Institute for Allergy and Immunology)H-Index: 2
Last. Tannishtha Reya (UCSD: University of California, San Diego)H-Index: 32
view all 4 authors...
Poorly differentiated aggressive myeloid diseases such as Acute Myelogenous Leukemia (AML) and blast crisis Chronic Myelogenous Leukemia (bcCML) are often resistant to standard therapy and associated with significantly poor survival in both children and adults. There is thus a significant need for a better understanding of the mechanisms that drive disease progression and for finding novel therapeutic targets. Thus, to determine the molecular effectors of myeloid leukemia growth in vivo, we carr...
Source
123456789